Edit
Multitude Therapeutics
https://www.multitudetherapeutics.info/Last activity: 19.10.2025
Active
Multitude Therapeutics. Unique MabArray platform for target discovery.
Location: United States
Employees: 1-10
Founded date: 2018
Investors 1
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
Mentions in press and media 2
| Date | Title | Description |
| 19.10.2025 | Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced... | AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in... |
| 17.10.2025 | Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR ... | AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in pat... |